Companies: 10,795·Total market cap: $144.5T
Celcuity Inc.

Celcuity Inc.

CELCNASDAQHealthcare● Active
$88.28
$-4.19(-4.53%)
Market Cap$4.3B
P/E Ratio
52W High$151.02
52W Low$11.275

Celcuity Inc. (CELC) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

celc · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Celcuity Inc. (CELC) measures how much investors pay for each dollar of the company's trailing earnings. CELC's current PE ratio of N/A is calculated by dividing its stock price of $88.28 by its TTM earnings per share of -$3.54.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-0.48
Based on 5 analysts
EPS (TTM)
-$3.54
TTM · diluted EPS
PEG Ratio
1.04
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Celcuity Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2015 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Celcuity Inc.
Celcuity Inc.You
CELC
$4.3BN/A-$3.54
Ascentage Pharma Group International
Ascentage Pharma Group International
AAPG
$1.6BN/A-$13.58
Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc.
APGE
$5.4BN/A-$4.22
CG Oncology, Inc. Common stock
CG Oncology, Inc. Common stock
CGON
$4.7BN/A-$2.08
Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc
CNTA
$6.1BN/A-$1.46
Disc Medicine, Inc.
Disc Medicine, Inc.
IRON
$2.6BN/A-$6.01
Legend Biotech Corporation
Legend Biotech Corporation
LEGN
$6.0BN/A-$1.61

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 11 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-3.37
2024-12-31
FY2024
$-2.83
2023-12-31
FY2023
$-2.69
2022-12-31
FY2022
$-2.62
2021-12-31
FY2021
$-2.21
2020-12-31
FY2020
$-0.92
2019-12-31
FY2019
$-0.72
2018-12-31
FY2018
$-0.74
2017-12-31
FY2017
$-0.84
2016-12-31
FY2016
$-0.49

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Celcuity Inc. (CELC) measures how much investors pay for each dollar of the company's trailing earnings. CELC's current PE ratio of N/A is calculated by dividing its stock price of $88.28 by its TTM earnings per share of -$3.54.

PE Ratio = Stock Price ÷ EPS (TTM)
= $88.28 ÷ -$3.54 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

CELC pe ratio · 6 questions

CELC's current PE ratio is N/A as of 2026-06-08, based on a stock price of $88.28 and TTM EPS of -$3.54. Data sourced from Financial Modeling Prep via CELC's SEC 10-K and 10-Q filings.

CELC PE ratioWhat is CELC PE ratioCurrent PE ratio of CELCCELC PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Celcuity Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08